mbiomics GmbH
Germany
- Munich, Bavaria
- 24/03/2023
- Series A
- $13,945,000
We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.
- Industry Biotechnology Research
- Website https://mbiomics.com/
- LinkedIn https://www.linkedin.com/company/mbiomics-gmbh/
Related People
Laura FigullaCo Founder
Germany -
Munich, Bavaria
With 15+years of life science entrepreneurial and strategy&transactions consulting experience, including venture capital, M&A, digital transformation and innovation strategy, as well as in-depth industry expertise and strong public relations skills, I am truly passionate about creating company strategies, vision and enabling high-performing teams. My career background allows me to provide strategic, fundraising, and business operations insight for innovative life sciences players, in particular around digital health and biotechnology business models.
Tribe Stays | $2,800,000 | (Nov 18, 2025)
No Barrier Medical Translation | $2,700,000 | (Nov 18, 2025)
PowerLattice | $25,000,000 | (Nov 18, 2025)
Shipday | $7,000,000 | (Nov 18, 2025)
Muse Software | $4,500,000 | (Nov 18, 2025)
Artios | $115,000,000 | (Nov 18, 2025)
Scripta Therapeutics | $12,000,000 | (Nov 18, 2025)
Self Labs | $9,000,000 | (Nov 18, 2025)
Obello | $8,500,000 | (Nov 18, 2025)
AlertD | $3,000,000 | (Nov 18, 2025)
Skeletalis, Inc. | $8,000,000 | (Nov 18, 2025)
Span(US) | $25,000,000 | (Nov 18, 2025)